Arcutis Biotherapeutics, Inc. ARQT Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Bristol-Myers SquibbBMY

$359M+63.2%

BridgeBio PharmaBBIO

——

Revenue$105.4M+60.1%

Gross profit$95.6M+67.7%

Operating income-$9.1M+62.9%

Net income-$11.3M+54.9%

EPS (diluted)-$0.09+55.0%

Cash & equivalents$35.1M-34.7%

Total debt$114.7M+3.5%

Total equity$189.6M+32.9%

Total assets$460.0M+33.7%

Operating cash flow$2.2M+107%

CapEx--100%

Free cash flow$2.2M+107%

Market cap$3.29B+57.5%

Gross margin90.9%+2.5pp

Operating margin-12%-5.7pp

Net margin-13.9%-6.6pp

FCF margin-52.5%-21.9pp

Return on equity-28.2%-13.0pp

Debt / equity0.6×-0.2×

Current ratio2.7×-0.9×

Reported directly by Arcutis Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Arcutis Biotherapeutics, Inc.'s proceeds from sale and maturity of available for sale securities?: Arcutis Biotherapeutics, Inc. (ARQT) reported proceeds from sale and maturity of available for sale securities of $50.82M in Q1 2026.
How has Arcutis Biotherapeutics, Inc.'s proceeds from sale and maturity of available for sale securities changed year-over-year?: Arcutis Biotherapeutics, Inc.'s proceeds from sale and maturity of available for sale securities decreased by 25.8% year-over-year, from $68.47M to $50.82M.